Multiple Myeloma / IMS 10/08/2026

Part 1: Earlier CAR T-Cell Therapy in Multiple Myeloma: Identifying Patients at First Relapse

Key Points

  • CAR T-cell therapy is moving into earlier lines of multiple myeloma treatment, with efficacy and progression-free survival benefits supporting consideration at first relapse, particularly among patients with high-risk disease.
  • Disease biology and treatment refractoriness may be more informative than line of therapy alone, with functional or genomic high-risk disease, extramedullary disease, and CD38/lenalidomide double-refractoriness prompting early referral.
  • Age and transplant eligibility should not automatically exclude patients from CAR T-cell therapy; instead, clinicians should consider cardiopulmonary reserve, disease kinetics, response to bridging therapy, and the patient’s ability to tolerate treatment-related toxicities.

The treatment landscape for multiple myeloma continues to shift toward earlier use of T-cell–redirecting therapies, including CAR T-cell therapy and bispecific antibodies. In this discussion, Hamza Hashmi, MD, of Memorial Sloan Kettering Cancer Center, and Ajai Chari, MD, of UCSF Health, review the depth and durability of responses observed with T-cell–redirecting therapies and the feasibility of introducing these approaches earlier in the treatment course. Long-term follow-up presented at the 2026 International Myeloma Society (IMS) meeting, held in Glasgow, Scotland, from September 23–26, further highlighted the potential for durable disease control following a single CAR T-cell infusion.

Importantly, Dr. Chari highlighted that earlier referral does not necessarily mean every patient should receive CAR T-cell therapy at second line. Instead, patient selection should increasingly incorporate disease biology, treatment response, and individual risk factors. Patients with functional or genomic high-risk disease, extramedullary disease (EMD), or particularly poor expected outcomes with available therapies may warrant consideration for CAR T-cell therapy as early as first relapse.

Identifying Patients Who May Benefit From Early Referral

For community clinicians, one important consideration is whether to refer a patient for CAR T-cell therapy at biochemical progression, clinical relapse, or even before overt relapse in patients with particularly high-risk disease. Dr. Chari noted that T-cell–redirecting therapies appear more effective when used earlier, potentially reflecting better T-cell function, less T-cell exhaustion, and a more favorable tumor-to-T-cell ratio. He also emphasized that safety may be improved when CAR T-cell therapy is administered before myeloma becomes rapidly progressive or otherwise difficult to control. Patients who relapse within approximately 3 years of induction, transplant, and maintenance may represent a functionally high-risk population, while genomic high-risk disease and EMD provide additional reasons to consider early referral.

Treatment refractoriness is another increasingly important consideration. In particular, patients who are refractory to both a CD38-directed therapy and lenalidomide may have limited treatment options and poor outcomes with conventional approaches. Drs. Chari and Hashmi highlighted consistent findings across multiple studies suggesting that CD38/lenalidomide double-refractory disease can be associated with progression-free survival of only several months, even when it occurs relatively early in the disease course.

Assessing CAR T-Cell Eligibility Beyond Transplant Criteria

Eligibility for CAR T-cell therapy should also be distinguished from traditional transplant eligibility, Dr. Chari said. Older age, prior transplant ineligibility, or certain comorbidities do not necessarily preclude a patient from receiving CAR T-cell therapy. The discussion emphasized that age alone should not be considered a contraindication, including older adults who may not be ideal candidates for high-dose melphalan and autologous transplant. Instead, clinicians should assess whether the patient has sufficient cardiopulmonary reserve to tolerate potential cytokine release syndrome (CRS), including hypotension and hypoxia. Renal dysfunction may not automatically exclude a patient, although overall clinical status remains critical.

Disease kinetics are particularly important when determining whether a patient can safely proceed through leukapheresis, manufacturing, lymphodepletion, and infusion. Patients with rapidly explosive disease or extensive EMD may deteriorate during this process and may therefore require an alternative treatment strategy. Bridging therapy can help control disease following apheresis while the CAR T-cell product is manufactured, but clinicians should reassess patients throughout this period. 

A patient who develops substantial frailty, a new serious medical complication, or inadequate disease control during bridging may no longer be an appropriate candidate for CAR T-cell therapy. Conversely, patients with controlled disease and adequate functional and cardiopulmonary reserve may remain candidates even though they would not have met the traditional transplant criteria, the doctors noted. 

Referral Should Occur Before Disease Becomes Uncontrolled

As CAR T-cell therapy moves into earlier lines of multiple myeloma treatment, timely referral is becoming an increasingly important component of relapse management. The goal is not simply to administer CAR T-cell therapy to every patient at first relapse, but to identify those for whom the potential durability and treatment-free interval justify early consideration, Dr. Chari said. High-risk disease biology, early relapse, EMD, and CD38/lenalidomide double-refractoriness may all support referral before the disease becomes difficult to control. At the same time, age and historical transplant eligibility should not serve as standalone exclusion criteria.